- Home
- GNW vs CPRX Comparison
GNW vs CPRX Comparison
Compare GNW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | CPRX |
|---|---|---|
| Founded | 1871 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2004 | 2006 |
Fundamental Metrics
Financial Performance| Metric | GNW | CPRX |
|---|---|---|
| Price | $8.00 | $23.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | 0.54 | ★ 1.68 |
| Revenue | ★ $7,301,000,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | N/A | $9.77 |
| P/E Ratio | $15.30 | ★ $14.53 |
| Revenue Growth | 0.08 | ★ 16.39 |
| 52 Week Low | $5.99 | $19.05 |
| 52 Week High | $9.28 | $26.56 |
Technical Indicators
Market Signals| Indicator | GNW | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.13 | 44.50 |
| Support Level | $6.70 | $22.46 |
| Resistance Level | $8.18 | $24.86 |
| Average True Range (ATR) | 0.27 | 0.99 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 11.30 | 40.82 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.